Banner Publications MH200828 N141

Publications

Results found: 6690

Showing results: 5601 - 5650

The EMBO journal

Dual role of MutS glutamate 38 in DNA mismatch discrimination and in the authorization of repair.

25-01-2006
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.

20-01-2006
The EMBO journal

CLIP-170 facilitates the formation of kinetochore-microtubule attachments.

11-01-2006
The Journal of biological chemistry

The rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development.

06-01-2006
Carcinogenesis

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

01-01-2006
Nature reviews. Cancer

Paradoxical roles of the immune system during cancer development.

01-01-2006
EMBO reports

Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody.

01-01-2006
Nature reviews. Cancer

KLF4, p21 and context-dependent opposing forces in cancer.

01-01-2006
Biomedical chromatography : BMC

A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry.

01-01-2006
Die Pharmazie

Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.

01-01-2006
Trends in pharmacological sciences

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

01-01-2006
Trends in pharmacological sciences

The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.

01-01-2006
Nucleic acids research

Human and mouse oligonucleotide-based array CGH

16-12-2005
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

10-12-2005
Nucleic acids research

Rapid and quantitative detection of homologous and non-homologous recombination events using three oligonucleotide MLPA.

09-12-2005
The Journal of cell biology

The Rac activator Tiam1 is required for (alpha)3(beta)1-mediated laminin-5 deposition, cell spreading, and cell migration.

05-12-2005
The Journal of cell biology

Nesprin-3, a novel outer nuclear membrane protein, associates with the cytoskeletal linker protein plectin.

05-12-2005
Cell

A genomic and functional inventory of deubiquitinating enzymes.

02-12-2005
Cellular and molecular life sciences : CMLS

Dissection of cytotoxic and helper T cell responses.

01-12-2005
Therapeutic drug monitoring

Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.

01-12-2005
PDA journal of pharmaceutical science and technology

Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.

01-12-2005
Molecular and cellular biology

Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.

01-12-2005
Trends in pharmacological sciences

An emerging role for PtdIns(4,5)P2-mediated signalling in human disease.

01-12-2005
Cancer cell

Mitogen requirement for cell cycle progression in the absence of pocket protein activity.

01-12-2005
Current gene therapy

Prospects and limitations of T cell receptor gene therapy.

01-12-2005
Cell cycle (Georgetown, Tex.)

CDK-dependent stabilization of Cdc6: linking growth and stress signals to activation of DNA replication.

01-12-2005
British journal of cancer

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.

28-11-2005
Oncogene

Retroviral insertional mutagenesis: past, present and future.

21-11-2005
Rapid communications in mass spectrometry : RCM

Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

16-11-2005
International journal of radiation oncology, biology, physics

Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy.

15-11-2005
Methods in enzymology

Functional annotation of deubiquitinating enzymes using RNA interference.

09-11-2005
Nature cell biology

The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene.

01-11-2005
The Journal of pharmacology and experimental therapeutics

Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.

01-11-2005
European journal of cancer (Oxford, England : 1990)

Quality of life among long-term breast cancer survivors: a systematic review.

01-11-2005
Breast cancer research and treatment

Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.

01-11-2005
Clinical pharmacokinetics

Clinical pharmacokinetics of cyclophosphamide.

20-10-2005
British journal of cancer

No common denominator for breast cancer lymph node metastasis.

17-10-2005
PDA journal of pharmaceutical science and technology

Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.

13-10-2005
Nederlands tijdschrift voor geneeskunde

[Rapid tracing of new patients with cancer through the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA) in order to freeze tumour material for molecular-epidemiological research].

01-10-2005
Cell cycle (Georgetown, Tex.)

p16INK4a as a second effector of the telomere damage pathway.

01-10-2005
Anti-cancer drugs

Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

01-10-2005
Cancer investigation

Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.

01-10-2005
Cancer chemotherapy and pharmacology

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.

01-10-2005
Cancer chemotherapy and pharmacology

Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).

01-10-2005
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.

01-10-2005
Investigational new drugs

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

01-10-2005
Cell

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

23-09-2005
International journal of cancer

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

20-09-2005
Cancer research

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development

15-09-2005
Menopause (New York, N.Y.)

Are cause of subfertility and in vitro fertilization treatment risk factors for an earlier start of menopause?

08-09-2005

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.